Enterprise Value
526M
Cash
164M
Avg Qtr Burn
-20.58M
Short % of Float
24.49%
Insider Ownership
9.41%
Institutional Own.
74.31%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JELMYTO® (mitomycin) Details Carcinoma , Cancer | Approved Quarterly sales | |
UGN-102 (mitomycin) Details Bladder cancer, Cancer | NDA Submission | |
UGN-103 Details Bladder cancer, Cancer | Phase 3 Initiation |